Core Viewpoint - The announcement details a change in the equity stake of the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., indicating a decrease in ownership percentage from 61.56% to 60.85% due to the repurchase and cancellation of restricted shares [1][2]. Group 1 - The controlling shareholder's equity stake decreased from 61.56% to 60.85% [1][2]. - The change in equity does not trigger mandatory tender offer obligations [1]. - The equity change is attributed to the repurchase and cancellation of restricted shares, which affected the total share capital of the company [2]. Group 2 - Heilongjiang Chuangda Group's shareholding decreased from 579,885,300 shares to 572,558,277 shares [1][2]. - The equity change occurred during the period of October 12, 2023, to December 8, 2023 [1]. - The company assures that the change in shareholding will not affect the status of the controlling shareholder or actual controller [2].

证券代码：601117 股票简称：中国化学 公告编号：临 2025-039 中国化学工程股份有限公司 关于 2022 年限制性股票激励计划部分限制性股票 回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ? 回购注销原因：根据中国化学工程股份有限公司（以下 简称"公司"）《2022 年限制性股票激励计划（草案）》（以 下简称"《激励计划》"）、《2022 年限制性股票激励管理办 法》《2022 年限制性股票激励实施考核管理办法》等相关规定， 公司 19 名激励对象存在异动情况，不再符合激励条件，应对其 所授予的限制性股票总计 184.80 万股进行回购注销。本次注销 完成后，公司总股本将由 6,108,725,362 股变更为 6,106,877,362 股。 ? 本次注销股份的有关情况： 单位：万股 回购股份数量（万股） 注销股份数量（万股） 注销日期 ? 实施情况：预计本次限制性股票将于 2025 年 8 月 7 日 完成注销。 一、本次限制性股票回购注销的决策与信息披露 议及第五届监事 ...

Group 1 - The company has announced the adjustment of the conversion price for its convertible bonds due to the repurchase and cancellation of restricted stocks [1][3] - The previous conversion price was set at RMB 7.51 per share, which has been adjusted to RMB 7.52 per share effective from August 4, 2025 [1][4] - The company issued 29 million convertible bonds on March 16, 2023, with a total amount of RMB 2.9 billion, maturing on March 15, 2029 [1][2] Group 2 - The board of directors approved the repurchase and cancellation of 5.7978 million restricted stocks, which accounts for 0.23% of the company's total share capital, due to unmet performance targets [2] - The repurchase price will be based on the grant price plus the interest from bank deposits [2] - The completion of the repurchase and cancellation was processed by the China Securities Depository and Clearing Corporation on July 31, 2025 [2]

证券代码：300426 证券简称：华智数媒 公告编号：2025-047 浙江华智数媒传媒股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 第二期限制性股票激励计划已获授但尚未解除限售的限制性股票 4,859,400 股，占回 购前公司股本总数的 1.0674%，涉及激励对象 6 人，回购价格为 3.48 元/股，回购金 额 16,910,712.00 元，所需资金为公司自有资金。 完成了上述限制性股票的回购注销手续。 一、本次回购注销限制性股票的审批情况 公司第四届董事会第三十九次会议、第四届监事会第三十八次会议，以及 2023 年第四次临时股东大会，分别审议通过了《关于回购注销 2019 年第二期限制性股票 激励计划限制性股票的议案》。鉴于公司 2021 年度、2022 年度业绩未达到 2019 年 第二期激励计划规定的第二个、第三个解除限售期解除限售的相关条件，根据《2019 年第二期限制性股票激励计划（草案）》的相关规定，公司决定对 2019 年第二期限 制性股票激励计划涉及的 6 名激励对象所持有的已获授但尚未解锁的限制性股票共 ...

Core Viewpoint - The company has completed the repurchase and cancellation of 4.8594 million restricted stock units from the 2019 second phase incentive plan, which accounts for 1.0674% of the total share capital before the repurchase [1] Summary by Relevant Sections - **Repurchase Details** - The repurchase price was set at 3.48 yuan per share, totaling 16.9107 million yuan [1] - The total share capital of the company has changed from 455 million shares to 450 million shares after the cancellation [1] - **Impact on Financials** - The repurchase and cancellation will not have a significant impact on the company's financial status and operating results [1]

Group 1 - The second extraordinary general meeting of shareholders was held on July 30, 2025, at the company's office in Ma'anshan, Anhui Province [2][3] - All resolutions presented at the meeting were approved without any objections [2][4] - The meeting was presided over by the chairman, Jiang Yuxiang, with full attendance from the board of directors and supervisors [3][4] Group 2 - The company approved a supplementary agreement for the product purchase and sales agreement with China Baowu Steel Group for the years 2025-2027 [4] - The company also approved a proposal to repurchase and cancel a portion of restricted stock, totaling 21,025,600 shares at a repurchase price of 2.29 yuan per share [4][8] - The total registered capital will be reduced by 21,423,400 yuan following the cancellation of the restricted stock [8] Group 3 - The company notified creditors about the capital reduction due to the stock repurchase, allowing them to claim debts within specified timeframes [9][10] - Creditors have 30 days from receiving the notice or 45 days from the announcement date to assert their claims [9][10]

证券代码：603439 证券简称：贵州三力 公告编号：2025-044 贵州三力制药股份有限公司 关于回购注销部分限制性股票减资暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原因 二、需债权人知晓的相关信息 的第四届董事会第十一次会议和第四届监事会第十次会议，审议通过了《关于回 购注销部分限制性股票的议案》，同意公司以自有资金回购注销2024年限制性股 票激励计划中部分已获授但尚未解除限售的限制性股票合计60,000股。具体内容 详见公司2025年3月29日于上海证券交易所网站（www.sse.com.cn）披露的《贵 州三力制药股份有限公司关于回购注销部分限制性股票的公告》（公告编号： 暨通知债权人的公告》（公告编号：2025-008）。截止本公告披露日，相关股份 尚未完成注销。 第十一次会议，审议通过了《关于2021年限制性股票激励计划第三个解除限售期 解除限售条件未成就暨回购注销的议案》，同意公司以自有资金回购注销2021 年限制性股票激励计划第三个解除限售期中已获授但解除限售条件未 ...

证券代码：002402 证券简称：和而泰 公告编号：2025-053 深圳和而泰智能控制股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳和而泰智能控制股份有限公司（以下简称"公司"）于2025年7月29日召开第 六届董事会第二十六次会议和第六届监事会第二十四次会议审议通过了《关于回购注 销部分已授予但尚未解除限售的限制性股票暨减资的议案》，公司董事会同意对4名因 个人原因离职不再符合激励条件的激励对象已授予但尚未解除限售的限制性股票共 尚需提交公司股东大会审议，现将有关情况公告如下： 一、 股权激励计划已履行的相关审议程序 议，审议通过了《关于<2022年限制性股票激励计划（草案）>及其摘要的议案》等相关 议案，公司独立董事对此发表了同意的独立意见，北京君合（杭州）律师事务所就此事 项 出 具 了 法 律 意 见 书 。 具 体 内 容 详 见 2022 年 12 月 2 日 登 载 于 巨 潮 资 讯 网 （www.cninfo.com.cn）的相关公告文件。 励计划激励对象名单》，公示时间为2022年12月2日-2022年12月12日，公 ...

Core Viewpoint - The company has completed the repurchase and cancellation of part of the restricted stock under the 2023 stock option and restricted stock incentive plan, with a total repurchase amount of RMB 1,836,245.60, resulting in a reduction of the total share capital [1][10][14]. Summary by Sections Stock Incentive Plan Overview - The company approved the 2023 stock option and restricted stock incentive plan on July 10, 2023, and the plan was subsequently authorized by the shareholders' meeting [1][2][3]. - The plan includes performance assessment criteria for the release of restricted stocks, with specific performance targets set for the years 2023 to 2025 [10]. Repurchase and Cancellation Details - The repurchase and cancellation of restricted stocks were conducted due to the failure to meet the performance targets for the year 2024, which required a revenue growth rate of no less than 44% compared to 2022 [10][11]. - The total number of restricted stocks repurchased was 8,400 shares, and the adjusted repurchase price was set at RMB 5.56 per share [12][14]. Changes in Share Capital Structure - Following the repurchase, the company's share capital structure changed, with the number of restricted shares with limited sale conditions decreasing from 24,243,087 to 23,912,827 shares [14]. - The total number of shares after the repurchase is 867,357,451 shares, maintaining compliance with listing requirements [14]. Financial Impact - The repurchase and cancellation of restricted stocks will not have a substantial impact on the company's financial status or operational results, nor will it affect the ongoing implementation of the incentive plan [14].

Core Viewpoint - The company, Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., is implementing a buyback and cancellation of 144,094 restricted stocks due to the departure of three employees, which represents 5.95% of the total stock under the incentive plan and 0.02% of the company's total share capital [1][2]. Group 1: Buyback and Cancellation Details - The buyback and cancellation are based on the provisions of the "Incentive Plan" and the "Management Measures for Equity Incentives of Listed Companies," which stipulate that restricted stocks cannot be released from restrictions if the employee has left the company [2][3]. - The total amount for the buyback is 1,186,181.80 yuan, sourced from the company's own funds [2][3]. - The cancellation of the stocks is expected to be completed by July 29, 2025, with the company having opened a dedicated securities account for this purpose [3]. Group 2: Impact on Share Capital Structure - Following the cancellation, the company's total share capital will decrease from 941,140,609 shares to 940,996,515 shares [3][4]. - The cancellation will not affect the controlling shareholder or the actual controller, and the company's equity distribution will still meet the listing requirements [4]. Group 3: Legal Compliance and Commitments - The board of directors confirmed that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of the incentive objects or creditors [4][5]. - The company has committed to handling any disputes arising from this buyback and cancellation responsibly [4][5].